Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial

Lavigne-Lissalde, G; Aya, A G; Mercier, F J; Roger-Christoph, S; Chauleur, C; Morau, E; Ducloy-Bouthors, A S; Mignon, A; Raucoules, M; Bongain, A; Boehlen, Françoise; De Moerloose, Philippe; Bouvet, S; Fabbro-Peray, P; Gris, J-C

doi:10.1111/jth.12844

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial
Authors		Lavigne-Lissalde, G Aya, A G Mercier, F J Roger-Christoph, S Chauleur, C Morau, E Ducloy-Bouthors, A S Mignon, A Raucoules, M Bongain, A Boehlen, Françoise De Moerloose, Philippe Bouvet, S Fabbro-Peray, P Gris, J-C show all authors [1 - 15]
Published in		Journal of thrombosis and haemostasis. 2015, vol. 13, no. 4, p. 520-529
Abstract		Case reports on recombinant human factor VIIa (rhuFVIIa) use in women with severe postpartum hemorrhage (PPH) showed encouraging results, but no randomized controlled trial (RCT) is available.
Keywords		Adult — Coagulants/administration & dosage/adverse effects/therapeutic use — Compassionate Use Trials — Dinoprostone/analogs & derivatives/therapeutic use — Drug Administration Schedule — Factor VIII/administration & dosage/adverse effects/therapeutic use — Female — France — Hemostatic Techniques/adverse effects — Humans — Hysterectomy — Infusions, Intravenous — Postpartum Hemorrhage/diagnosis/drug therapy/mortality — Pregnancy — Risk Factors — Severity of Illness Index — Switzerland — Time Factors — Treatment Failure — Venous Thrombosis/chemically induced
Identifiers		DOI: 10.1111/jth.12844 PMID: 25594352
Full text		Article (Published version) (245 Kb) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		Geneva Platelet Group (13)
Citation (ISO format)		LAVIGNE-LISSALDE, G et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. In: Journal of thrombosis and haemostasis, 2015, vol. 13, n° 4, p. 520-529. doi: 10.1111/jth.12844 https://archive-ouverte.unige.ch/unige:89774